Pieris Pharmaceuticals terminated a collaboration agreement with Servier due to a potential safety concern in a clinical study, and they will discontinue development of a specific drug. They also announced potential milestone and royalty payments from partnerships with Boston Pharmaceuticals and Pfizer.